SMMT logo

Summit Therapeutics Inc. Common Stock


SMMT: Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.


Show SMMT Financials

Consumer Interest
SEC Filings

Recent trades of SMMT by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by SMMT's directors and management

Government lobbying spending instances

  • $30,000 Aug 03, 2020 Issue: Pharmacy
U.S. Patents

New patents grants

  • Patent Title: Antibacterial compounds Sep. 19, 2017
  • Patent Title: Antibacterial compounds Apr. 19, 2016
  • Patent Title: Compounds for the treatment of Mar. 08, 2016
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of SMMT in WallStreetBets Daily Discussion


Recent insights relating to SMMT

CNBC Recommendations

Recent picks made for SMMT stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in SMMT

Corporate Flights

Flights by private jets registered to SMMT